Committed to transforming the lives of patients with severe genetic and rare diseases


With its lentiviral-based gene therapies, T cell immunotherapy expertise and gene editing capabilities, bluebird bio has built an integrated product platform with broad potential application to severe genetic diseases and cancer. bluebird bio’s gene therapy clinical programs include its Lenti-D™ product candidate, currently in a Phase 2/3 study, called the Starbeam Study, for the treatment of childhood cerebral adrenoleukodystrophy, and its LentiGlobin® BB305 product candidate, currently in three clinical studies for the treatment of beta-thalassemia major and severe sickle cell disease. bluebird bio’s oncology pipeline is built upon the company’s leadership in lentiviral gene delivery and T cell engineering, with a focus on developing novel T cell-based immunotherapies, including chimeric antigen receptor (CAR T) and T cell receptor (TCR) therapies. bluebird bio’s lead oncology program, bb2121, is an anti-BCMA CAR T program partnered with Celgene. bb2121 is currently being studied in a Phase 1 trial for the treatment of relapsed/refractory multiple myeloma. bluebird bio also has discovery research programs utilizing megaTAL/homing endonuclease gene editing technologies with the potential for use across the company’s pipeline.


Year Invested: 2010
Location: Cambridge, Mass.
Visit: www.bluebirdbio.com

Recent News

May 23, 2017
bluebird bio Announces Collaboration with Duke University’s Robert J. Margolis, MD, Center for Health Policy on Value-Based Payment Framework for Gene Therapy

May 18, 2017
bluebird bio to Present New Data from LentiGlobinTM Clinical Studies at European Hematology Association (EHA) Annual Meeting

May 17, 2017
bluebird bio to Present Updated Clinical Results from Novel Anti-BCMA CAR T Cell Therapy bb2121 at American Society of Clinical Oncology (ASCO) Annual Meeting

Read More News

Associated Team Members

Robert Tepper, M.D.
Partner

Neil Exter
Partner

Philip Reilly, M.D., J.D.
Venture Partner